UCB is a global biopharmaceutical company with the ambition to transform the lives of people living with severe diseases. We focus on neurology and immunology disorders – putting patients at the center of our world. UCB is continuously working to advance science and embrace new knowledge.
At UCB we are leveraging scientific advances and skills in areas such as genetics, biomarkers and human biology. Patients inspire us to bring them value through cutting-edge science, innovative drugs, and practical solutions – so that they and their carers can get on with their lives. UCB is employing around 7,500 people in all four corners of the globe, inspired by patients and driven by science.
in the project
UCB is involved in the following project sections: WP6-Evaluation as industry Co-lead, in WP1 aiming to identify user needs, and WP5 the section of the project that will bring all components together. Additionally, we are represented in the Steering Committee.
Our contribution to the project
UCB will bring pharmaceutical experience to the project; in particular, Medical Affairs, Medical Information, Patient Support Programs, Clinical Development, Regulator.
A TASTE OF OUR WORK
UCB is a global biopharmaceutical company, headquartered in Belgium, with the ambition to transform the lives of people living with severe diseases.
Address: Brussels, Belgium